SCHEMBL1833222

SCHEMBL1833222

NC(=NS(=O)(=O)c1cccc2ccccc12)NCc1ccccn1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
F2 P00734 3/20 0.54
PRSS1 P07477 3/20 0.54
PRSS2 P07478 3/20 0.54
PRSS3 P35030 3/20 0.54
SMN1; SMN2 Q16637 5/20 0.50
MAPT P10636 1/20 0.48
KMT2A Q03164 2/20 0.43
CA2 P00918 2/20 0.43
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 2/20 0.41
GLA P06280 1/20 0.41
RUNX1 Q01196 1/20 0.41
CBFB Q13951 1/20 0.41
POLB P06746 1/20 0.41
ALOX15 P16050 1/20 0.41
CA1 P00915 1/20 0.41
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12658168 1.00 F2 (0.54) F2PRSS1PRSS2PRSS3SMN1; SMN2
SCHEMBL1833219 1.00 F2 (0.54) F2PRSS1PRSS2PRSS3SMN1; SMN2
SCHEMBL1830250 0.87 MAPK1 (0.46) SMN1; SMN2MAPTKMT2ACA2KDM4E
SCHEMBL12658062 0.87 MAPK1 (0.46) SMN1; SMN2MAPTKMT2ACA2KDM4E
SCHEMBL1830247 0.87 MAPK1 (0.46) SMN1; SMN2MAPTKMT2ACA2KDM4E
SCHEMBL1828515 0.80 SMN1; SMN2 (0.51) SMN1; SMN2KMT2ACA2KDM4EALDH1A1
SCHEMBL1828512 0.80 SMN1; SMN2 (0.51) SMN1; SMN2KMT2ACA2KDM4EALDH1A1
SCHEMBL13438569 0.79 F2 (0.54) F2PRSS1PRSS2PRSS3SMN1; SMN2
SCHEMBL1831727 0.79 F2 (0.54) F2PRSS1PRSS2PRSS3SMN1; SMN2
SCHEMBL1831724 0.79 F2 (0.54) F2PRSS1PRSS2PRSS3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1320520-B1 SULFONYLGUANIDINE GRUENENTHAL GMBH (DE) 2011-05-11 EP claimed
US-7671074-B2 Sulfonylguanidine compounds and pharmaceutical uses thereof GRUENENTHAL GMBH (DE) 2010-03-02 US claimed
US-20080085900-A1 SULFONYLGUANIDINE COMPOUNDS AND PHARMACEUTICAL USES THEREOF GRUENENTHAL GMBH (DE) 2008-04-10 US claimed
US-20030225084-A1 Sulfonylguanidine compounds and pharmaceutical uses thereof GRUENENTHAL GMBH (DE) 2003-12-04 US claimed
US-7671074-B2 Sulfonylguanidine compounds and pharmaceutical uses thereof GRUENENTHAL GMBH (DE) 2010-03-02 US disclosed
US-20080085900-A1 SULFONYLGUANIDINE COMPOUNDS AND PHARMACEUTICAL USES THEREOF GRUENENTHAL GMBH (DE) 2008-04-10 US disclosed
US-20030225084-A1 Sulfonylguanidine compounds and pharmaceutical uses thereof GRUENENTHAL GMBH (DE) 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085900-A1 SULFONYLGUANIDINE COMPOUNDS AND PHARMACEUTICAL USES THEREOF CACNA1G, CACNA1I, CACNA1A F2 2763/4885PRSS1 1446/4885PRSS2 1486/4885
US-20030225084-A1 Sulfonylguanidine compounds and pharmaceutical uses thereof CACNA1G, CACNA1I, CACNA1A F2 2763/4885PRSS1 1446/4885PRSS2 1486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.